.jpg)
Parkinson's disease has long been treated as a brain disorder, but the evidence tells a different story. The gut talks to the brain constantly through the vagus nerve, and the earliest changes in Parkinson's show up in the gut, not the brain. In Finland, researchers compared the gut bacteria of 72 people with Parkinson's to 72 healthy people and found a clear pattern: too little of a helpful bacteria called Prevotella and too much of a harmful family called Enterobacteria, and the more Enterobacteria a person had, the worse their balance and walking became. A 2020 study of the U.S. population found the same imbalance: people with Parkinson's had fewer of the bacteria that produce short-chain fatty acids, or SCFAs for short. SCFAs are small molecules made by healthy gut bacteria that calm inflammation, protect the lining of the gut, and support brain chemicals like dopamine. A 2024 study out of Canada confirmed it again, showing that carbohydrate digestion and SCFA production are both disrupted in Parkinson's. The exact species missing differ from country to country, but the missing job is always the same: making SCFAs. Constipation caused by this imbalance can show up seven years before the tremors and stiffness of Parkinson's begin. A landmark 2026 study from University College London took this a step further, testing stool samples from over 460 people, including patients, healthy people, and people who carry a Parkinson's-linked gene but have no symptoms yet. The same gut bacteria pattern seen in Parkinson's patients was already present, in a milder form, in about one in five healthy people with no diagnosis at all, and it lined up closely with early warning signs like depression, constipation, and poor sense of smell. In other words, the gut microbiome may flag Parkinson's risk years before a diagnosis is even possible. This is the naturopathic principle in action: it's all about the gut.
Genetics explains only about 2 percent of Parkinson's cases, and even a known genetic risk gene like LRRK2 mostly works by making the body more vulnerable to environmental chemicals. Pesticide exposure is the clearest driver. Paraquat, a weed killer, causes Parkinson's-like symptoms by damaging cells with free radicals, disabling the energy-producing parts of neurons, and triggering inflammation in the brain. In California's Central Valley, people who worked near paraquat spraying every year were more than twice as likely to develop Parkinson's, and the more paraquat they were exposed to, the higher that risk climbed. Farmers carry a special burden: they are regularly exposed to mixtures of several pesticides at once, which have barely been studied together, and these chemicals can linger in soil for up to seven years. Even everyday, non-farming exposure carries risk. Simply living within a mile of a golf course more than doubles the odds of developing Parkinson's, and sharing a water supply with a golf course nearly doubles it as well. Glyphosate, sold as Roundup, adds to the damage by killing off two of the most beneficial gut bacteria, Lactobacillus and Bifidobacterium. Rotenone, another common pesticide, causes the hallmark Parkinson's protein, alpha-synuclein, to clump together inside the nerves of the gut itself. These are not separate problems. Pesticide exposure and an unhealthy gut work together as one path toward Parkinson's disease.
What you eat actively shapes this risk. Dairy has one of the clearest links: people who eat the most dairy have a 40 percent higher risk of Parkinson's than people who eat the least, and every extra 200 grams of milk per day (roughly a cup) raises risk by another 17 percent. The likely reason is that dairy lowers uric acid, a natural antioxidant that appears to protect the brain in Parkinson's and non-organic dairy products have pesticides and other chemicals. High fructose corn syrup spikes blood sugar and may carry trace mercury, while artificial sweeteners disturb the gut microbiome, raise the risk of insulin resistance, and may speed up Parkinson's progression. Even a conventionally grown apple carries a hidden cost, since pesticides sprayed at the base of the tree end up inside the fruit itself and cannot be washed off. The protective side of the ledger is just as clear. The polyphenols found in berries appear to be some of the most protective compounds available for Parkinson's, and the catechins in green tea have been shown to delay symptom progression by as much as seven years. Parkinson's is increasingly described as a kind of diabetes of the brain, driven by insulin resistance in brain tissue, which is why diabetes drugs called GLP-1 agonists are now being tested as brain-protective treatments and have already shown improvement in motor symptoms in clinical studies.
Directly restoring the gut microbiome produces real, measurable improvement, and the newest research confirms it two different ways. First, fecal microbiota transplants (FMT), which transfer healthy donor stool into a patient's gut, have produced striking results in small studies from China, Israel, and the United States. In one Chinese trial, 10 of 11 patients improved dramatically, with their symptom scores falling by more than half over 12 weeks. A second Chinese study using a colonoscopy-based transplant cut symptom scores nearly in half within three months. FMT is not currently legal for this purpose in the United States, but a landmark alternative arrived in December 2025: a randomized, placebo-controlled trial gave 72 Parkinson's patients daily capsules of the two main SCFAs, propionic acid and butyric acid, along with a prebiotic fiber, for six months. Every treatment group showed a clinically meaningful drop in motor symptom scores, needed 15 percent less of their Parkinson's medication, and showed improved thinking and memory scores. Strikingly, this happened without dramatically changing which bacteria were present in the gut. The benefit came from repairing the gut lining, calming inflammation, and improving communication between gut and immune cells; proof that you do not need to rebuild the entire microbiome to get a real clinical benefit, you just need to restore its function. In the meantime, simple daily habits point the same direction: eating 30 different plant foods a week, favoring polyphenol-rich berries, and getting enough fermentable fiber all help the gut produce more of its own SCFAs. A feasibility study of a ketogenic diet, low in dairy and built around 80 percent fat, 15 percent protein, and 5 percent carbohydrate, lowered gut inflammation, raised SCFA production, and improved mitochondrial function, and 60 percent of participants had a clinically meaningful improvement in their total symptom score after just 12 weeks. Parkinson's disease is a disease of the gut. Reducing chemical exposure and actively restoring the microbiome are not side strategies; they are the treatment strategy.
References
Afzal, O., Dalhat, M. H., Altamimi, A. S. A., Rasool, R., Alzarea, S. I., Almalki, W. H., Murtaza, B. N., Iftikhar, S., Nadeem, S., Nadeem, M. S., & Kazmi, I. (2022). Green tea catechins attenuate neurodegenerative diseases and cognitive deficits. Molecules, 27(21), 7604. https://doi.org/10.3390/molecules27217604
Barnett, J. A., Bandy, M. L., & Gibson, D. L. (2022). Is the use of glyphosate in modern agriculture resulting in increased neuropsychiatric conditions through modulation of the gut-brain-microbiome axis? Frontiers in Nutrition, 9, 827384. https://doi.org/10.3389/fnut.2022.827384
Chen, M., Tao, L., McLean, J., & Lu, C. (2014). Quantitative analysis of neonicotinoid insecticide residues in foods: Implication for dietary exposures. Journal of Agricultural and Food Chemistry, 62(26), 6082–6090. https://doi.org/10.1021/jf501397m
Chen, Y., Xu, J., & Chen, Y. (2021). Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients, 13(6), 2099. https://doi.org/10.3390/nu13062099
Dorsey, E. R., & Bloem, B. R. (2024). Parkinson's disease is predominantly an environmental disease. Journal of Parkinson's Disease, 14(3), 451–465. https://doi.org/10.3233/JPD-230357
Dorsey, E. R., De Miranda, B. R., Hussain, S., Bloem, B. R., Elbaz, A., Llibre-Guerra, J., Lo, R. Y., Goldman, S. M., & Tanner, C. M. (2025). Environmental toxicants and Parkinson's disease: Recent evidence, risks, and prevention opportunities. The Lancet Neurology, 24(11), 976–986. https://doi.org/10.1016/S1474-4422(25)00287-X
Dufault, R., LeBlanc, B., Schnoll, R., Cornett, C., Schweitzer, L., Wallinga, D., Hightower, J., Patrick, L., & Lukiw, W. J. (2009). Mercury from chlor-alkali plants: Measured concentrations in food product sugar. Environmental Health, 8, 2. https://doi.org/10.1186/1476-069X-8-2
Hegelmaier, T., Duscha, A., Desel, C., Fuchs, S., Shapira, M., Amidror, S., Shan, Q., Stangl, G. I., Hirche, F., Kempa, S., Maifeld, A., Würtele, L.-M., Peplinski, J., Jauk, D., Naim, G., Shidlovsky, N., Cohen, A., Bennet, Y., Paschold, L., Dumitru, C. A., Obermüller-Jevic, U., Hustvedt, S.-O., Timmesfeld, N., Gold, R., Zapf, A., Binder, M., Sandalcioglu, I. E., Mostaghim, S., Przuntek, H., Segal, E., Yissachar, N., & Haghikia, A. (2025). Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: A randomized double-blind prospective study. Scientific Reports, 16, 315. https://doi.org/10.1038/s41598-025-29692-x
Jiang, W., Ju, C., Jiang, H., & Zhang, D. (2014). Dairy foods intake and risk of Parkinson's disease: A dose-response meta-analysis of prospective cohort studies. European Journal of Epidemiology, 29(9), 613–619. https://doi.org/10.1007/s10654-014-9921-4
Krzyzanowski, B., Mullan, A. F., Dorsey, E. R., et al. (2025). Proximity to golf courses and risk of Parkinson disease. JAMA Network Open, 8(5), e259198. https://doi.org/10.1001/jamanetworkopen.2025.9198
Kuai, X. Y., Yao, X. H., Xu, L. J., et al. (2021). Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation. Microbial Cell Factories, 20, 98. https://doi.org/10.1186/s12934-021-01589-0
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023). Pesticides and the microbiome-gut-brain axis: Convergent pathways in the pathogenesis of Parkinson's disease. Journal of Parkinson's Disease, 13(7), 1079–1106. https://doi.org/10.3233/JPD-230206
Menozzi, E., Ren, Y., Geiger, M., Macnaughtan, J., Avenali, M., Toffoli, M., Gilles, M., Calabrese, R., Mitrotti, P., Gallo, L., Famechon, A., Lucas Del Pozo, S., Mezabrovschi, R., Koletsi, S., Loefflad, N., Yalkic, S., Limbachiya, N., Clasen, F., Yildirim, S., Shoaie, S., Blottière, H., Morabito, C., David, A., Quinquis, B., Pons, N., Le Chatelier, E., Valzania, F., Cavallieri, F., Fioravanti, V., Toschi, G., Blandini, F., Almeida, M., Ehrlich, S. D., Meslier, V., & Schapira, A. H. V. (2026). Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals. Nature Medicine, 32, 2096–2106. https://doi.org/10.1038/s41591-026-04318-5
Metcalfe-Roach, A., Cirstea, M. S., Yu, A. C., Ramay, H. R., Coker, O., Boroomand, S., Kharazyan, F., Martino, D., Sycuro, L. K., Appel-Cresswell, S., & Finlay, B. B. (2024). Metagenomic analysis reveals large-scale disruptions of the gut microbiome in Parkinson's disease. Movement Disorders, 39(10), 1740–1751. https://doi.org/10.1002/mds.29959
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023). Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease. Ageing Research Reviews, 89, 101979. https://doi.org/10.1016/j.arr.2023.101979
Paul, K. C., Cockburn, M., Gong, Y., Bronstein, J., & Ritz, B. (2024). Agricultural paraquat dichloride use and Parkinson's disease in California's Central Valley. International Journal of Epidemiology, 53(1), dyae004. https://doi.org/10.1093/ije/dyae004
Scheperjans, F., Aho, V., Pereira, P. A., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola-Rautio, J., Pohja, M., Kinnunen, E., Murros, K., & Auvinen, P. (2015). Gut microbiota are related to Parkinson's disease and clinical phenotype. Movement Disorders, 30(3), 350–358. https://doi.org/10.1002/mds.26069
Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R., & Ifergane, G. (2021). Fecal microbiota transplant as a potential treatment for Parkinson's disease: A case series. Clinical Neurology and Neurosurgery, 207, 106791. https://doi.org/10.1016/j.clineuro.2021.106791
Suez, J., Korem, T., Zilberman-Schapira, G., Segal, E., & Elinav, E. (2015). Non-caloric artificial sweeteners and the microbiome: Findings and challenges. Gut Microbes, 6(2), 149–155. https://doi.org/10.1080/19490976.2015.1017700
Wallen, Z. D., Appah, M., Dean, M. N., Sesler, C. L., Factor, S. A., Molho, E., Zabetian, C. P., Standaert, D. G., & Payami, H. (2020). Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens. npj Parkinson's Disease, 6, 11. https://doi.org/10.1038/s41531-020-0112-6
Worster, K., Colgan, D., Vita, A., McClure, C., Buttolph, L., Hodges, R., Senders, A., Erlandsen, A., Elbarbry, F., & Zwickey, H. (2025). A mixed methods feasibility study of a ketogenic diet as treatment for Parkinson's disease. Frontiers in Nutrition, 12, 1601446. https://doi.org/10.3389/fnut.2025.1601446
Xue, L. J., Yang, X. Z., Tong, Q., Shen, P., Ma, S. J., Wu, S. N., Zheng, J. L., & Wang, H. G. (2020). Fecal microbiota transplantation therapy for Parkinson's disease. Medicine, 99(35), e22035. https://doi.org/10.1097/MD.0000000000022035
